# STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units

Study · id `cardio:ct-nct03385928` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03385928](<https://clinicaltrials.gov/study/NCT03385928>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03385928

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

## Technical summary

Registry record NCT03385928. Randomized; quadruple masking; primary purpose treatment. Start 2018-03-19 (actual); primary completion 2023-05-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 201 participants (enrolled count; ClinicalTrials.gov record NCT03385928, source copy `cardio:ctgov-nct03385928-2023-09-28`, retrieved 2026-10-26)
- Started: 2018-03-19 (actual) (ClinicalTrials.gov record NCT03385928, source copy `cardio:ctgov-nct03385928-2023-09-28`, retrieved 2026-10-26)
- Primary completion: 2023-05-28 (actual) (ClinicalTrials.gov record NCT03385928, source copy `cardio:ctgov-nct03385928-2023-09-28`, retrieved 2026-10-26)
- Completion: 2023-05-28 (actual) (ClinicalTrials.gov record NCT03385928, source copy `cardio:ctgov-nct03385928-2023-09-28`, retrieved 2026-10-26)
- Countries: Australia; Finland; New Zealand; Taiwan; Vietnam (ClinicalTrials.gov record NCT03385928, source copy `cardio:ctgov-nct03385928-2023-09-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03385928-2023-09-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units
- Condition: Intracerebral Haemorrhage
- Intervention (Drug): Tranexamic Acid
- Intervention (Drug): Normal saline
- Lead sponsor: Neuroscience Trials Australia
- Lead sponsor class: OTHER
- Collaborator: The Florey Institute of Neuroscience and Mental Health
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Neuroscience Trials Australia (`cardio:org-neuroscience-trials-australia`)
- Registry lists this organization as a collaborator: The Florey Institute of Neuroscience and Mental Health (`cardio:org-the-florey-institute-of-neuroscience-and-mental-health`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Tranexamic acid versus placebo in individuals with intracerebral haemorrhage treated within 2 h of symptom onset (STOP-MSU): an international, double-blind, randomised, phase 2 trial (`cardio:pubmed-38648814`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1bd8a7124a13ddffc7b2d33f95475abdf03e625ca9e0149194fcd13ce3fd6c13
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
